ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OLGC Orthologic (MM)

0.865
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Orthologic (MM) NASDAQ:OLGC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.865 0 01:00:00

UBS Global Life Sciences Conference to Webcast OrthoLogic Presentation

19/09/2005 7:15pm

PR Newswire (US)


Orthologic (MM) (NASDAQ:OLGC)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Orthologic  (MM) Charts.
TEMPE, Ariz., Sept. 19 /PRNewswire-FirstCall/ -- OrthoLogic, Inc. (NASDAQ:OLGC) announced today that its presentation at the UBS Global Life Sciences Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.orthologic.com/. OrthoLogic management will provide an overview of the Company and an update on its lead compound for tissue and bone healing, Chrysalin(R). The presentation will be delivered at 10:00 a.m. EDT on Monday, September 26, 2005 from The Grand Hyatt Hotel in New York City. The presentation will be archived for 30 days. OrthoLogic is a biotechnology company focused on the development and commercialization of the novel synthetic peptide Chrysalin(R) (TP508) in three lead indications, all of which represent areas of significant unmet medical need -- fracture repair, diabetic foot ulcer healing and cartilage defect repair. Based on the Company's pioneering scientific research of the natural healing cascade, OrthoLogic has become the leading company focused on tissue and bone repair. OrthoLogic is committed to developing a pipeline of novel peptides and other molecules aimed at helping patients with equally under-served conditions. The Company maintains exclusive worldwide rights for Chrysalin. OrthoLogic's corporate headquarters are in Tempe, Arizona. For more information, please visit the company's Web site: http://www.orthologic.com/. Editors' Note: This press release is also available under the Investor section of the Company's website at: http://www.orthologic.com/. DATASOURCE: OrthoLogic, Inc. CONTACT: Media: Lauren Tortorete of Biosector 2, +1-212-845-5609; or Investors: Melanie Friedman of Stern Investor Relations, +1-212-362-1200 Web site: http://www.orthologic.com/

Copyright

1 Year Orthologic (MM) Chart

1 Year Orthologic  (MM) Chart

1 Month Orthologic (MM) Chart

1 Month Orthologic  (MM) Chart

Your Recent History

Delayed Upgrade Clock